Topiramate-Responsive Headache Due to Idiopathic Intracranial Hypertension in Behçet Syndrome

A 14‐year‐old adolescent was seen with an 8‐month history of almost daily incapacitating headaches due to idiopathic intracranial hypertension in Behçet syndrome. All his clinical signs and symptoms, including headache, resolved 2 to 4 weeks after topiramate was initiated. An effect on carbonic anhy...

Full description

Saved in:

Bibliographic Details
Published in:	Headache Vol. 44; no. 5; pp. 436 - 437
Main Authors:	Palacio MD, Enrique, Rodero, Lucia, Pascual, Julio
Format:	Journal Article
Language:	English
Published:	350 Main Street , Malden , MA 02148 , USA Blackwell Science Inc 01-05-2004 Blackwell
Subjects:	Adolescent Anticonvulsants - therapeutic use Behcet Syndrome - complications Behçet syndrome Biological and medical sciences carbonic anhydrase Fructose - analogs & derivatives Fructose - therapeutic use Headache - drug therapy Headache - etiology Humans intracranial hypertension Male Medical sciences Neurology Pseudotumor Cerebri - complications topiramate Vascular diseases and vascular malformations of the nervous system Headache Topiramate Skin disease Cardiovascular disease Lyases Anticonvulsant Genital diseases Vascular disease Vasculitis Pain Systemic disease carbonic anhydrase Benign intracranial hypertension Neurological disorder Cerebrovascular disease Nervous system diseases Enzyme Stomatology Intracranial hypertension Behçet syndrome Cerebral disorder Eye disease Central nervous system disease Carbonate dehydratase Carbon-oxygen lyases Hydro-lyases
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A 14‐year‐old adolescent was seen with an 8‐month history of almost daily incapacitating headaches due to idiopathic intracranial hypertension in Behçet syndrome. All his clinical signs and symptoms, including headache, resolved 2 to 4 weeks after topiramate was initiated. An effect on carbonic anhydrase isoenzymes II and IV, reducing cerebrospinal fluid production, could potentially explain the beneficial effect of topiramate in intracranial hypertension. Further studies are necessary, however, to confirm the significance of topiramate in this indication.
Bibliography:	istex:EF9EDD588A434D2726D289D3031E478731177E99 ArticleID:HEAD04095 ark:/67375/WNG-P32SS1R8-S From the Department of Neurology, University Hospital M de Valdecilla (UC), Santander, Spain. ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0017-8748 1526-4610
DOI:	10.1111/j.1526-4610.2004.04095.x